Ronak Gor, DO
Urology · Voorhees, NJNPI 1558657924
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 97.3% of it on its own, with 20 other manufacturers making up the rest. Among urology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 240 payments — averaging $431.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$101K
- Medtronic$922
- Teleflex LLC$440
- Neotract Inc.$421
- Coloplast$165
- Davol Inc.$145
- plus $661 from 15 others
Across 1 payment — averaging $710.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$710
What the payments were for
- Consulting fees$23,30022%
- Speaking & faculty fees$58,08556%
- Travel & lodging$12,54012%
- Food & beverage$9,7189%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 177 | $100,889 |
| Medtronic(2 entities) | 17 | $922 |
| Teleflex LLC | 8 | $440 |
| Neotract Inc. | 9 | $421 |
| Coloplast | 2 | $165 |
| Davol Inc. | 2 | $145 |
| Calyxo, Inc. | 1 | $145 |
| Cook Medical LLC | 1 | $88 |
| Ferring Pharmaceuticals Inc. | 2 | $84 |
| Astellas Pharma US Inc | 4 | $58 |
| Endo Pharmaceuticals Inc. | 4 | $54 |
| Axonics, Inc. | 2 | $41 |
| Convatec Inc. | 1 | $35 |
| Dendreon Pharmaceuticals LLC | 2 | $33 |
| Intuitive Surgical | 1 | $28 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| KCI USA, Inc. | 1 | $17 |
| Hollister Incorporated | 1 | $16 |
| ABC Home Medical Supply, Inc. | 1 | $16 |
| Valencia Technologies Corporation | 2 | $15 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMS 800 Artificial Urinary Sphincter$18,423
- AdVance XP$14,099
- AMS$10,512
- GENERAL ERECTILE DYSFUNCTION$10,335
- TACTRA$8,641
- AMS 700 CXR RTE KIT$6,048
- AMS 700$3,292
- GreenLight XPS$800
- GENERAL - THERAPIES$778
- LithoVue$442
- UroLift$398
- INTERSTIM$329
- GENERAL DBS$203
- CVAC Aspiration System$145
- GENERAL KIDNEY STONE DISEASE$144
- ALTIS$144
- ARISTA AH FLEXITIP$106
How this compares
$103,643 in reported general payments places this provider in the 95th percentile of 401 urology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 126 | $93,783 |
| GemtesaVibegron | 20 | $16,945 |
| Mirabegron ErMirabegron | 13 | $6,228 |
| Tamsulosin Hcl | 175 | $2,976 |
| Trospium Chloride | 34 | $1,563 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 52 | $920 |
| Solifenacin Succinate | 19 | $797 |
| Oxybutynin Chloride | 26 | $680 |
| Finasteride | 50 | $461 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 33 | $396 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 65 | $165 |
| Oxycodone Hcl | 47 | $94 |
| Doxycycline Hyclate | 11 | $46 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $58 | $93,783126 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $18 | $16,94520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 401 urology providers in New Jersey.
Other urology in Voorhees
- Jayram KrishnanVoorhees$87K
- Michael StifelmanHackensack$1.4M
- Gordon BrownCherry Hill$1.3M
- Thomas MuellerLinwood$1.1M
- David SussmanLinwood$802K
- Michael IngberDenville$530K
- Ravi MunverHackensack$529K
- Grannum SantBridgewater$487K
- Mutahar AhmedMaywood$414K
- Kevin GioiaRumson$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.